Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended						12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 STA Instruments Instruments	Dec. 31, 2012 Options	Dec. 31, 2013 Minimum	Dec. 31, 2012 Minimum	Dec. 31, 2013 Maximum	Dec. 31, 2012 Maximum	Dec. 31, 2013 Corporate Joint Venture	Sep. 30, 2013 Corporate Joint Venture
Summary of Significant Accounting Policies (Textual) [Abstract]
Warranty expense	$ 97,234	$ 87,544
Non-Warranty repair income	118,344	107,868
Write-off of Investment		76,319
Advertising expenses	30,104	51,412
Weighted-average fair value of the individual options granted	$ 1.62	$ 0.95
Payment of materials in advance	2,308,000	2,827,000
Rate of shareholder of the company						5.00%
Company purchased from supplier	3,026,041	1,966,077
Owed by company	1,024,653	808,908
Long-lived assets for impairment	0	0
Investment on the equity									45.50%	50.00%
Common stock, shares issued	17,759,540	16,563,306							2,000,000
Gain on Dilutive Effect on Medical Joint Venture stock issuance	$ 1,363,650
Estimated useful lives					5 years		7 years
Impairment periodically								20.00%
Outstanding options and warrants				1,523,740
Number of instruments on purchase agreement			12,000
Number of remaining instruments on purchase agreement			6,611